Y Intercept Hong Kong Ltd acquired a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) in the 1st quarter, Holdings Channel reports. The institutional investor acquired 45,192 shares of the biopharmaceutical company’s stock, valued at approximately $1,433,000.
A number of other hedge funds also recently bought and sold shares of CLDX. Wilmington Savings Fund Society FSB purchased a new position in Celldex Therapeutics in the third quarter worth about $42,000. Russell Investments Group Ltd. increased its position in shares of Celldex Therapeutics by 27.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 501 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Celldex Therapeutics during the 3rd quarter valued at about $63,000. Kestra Advisory Services LLC bought a new position in shares of Celldex Therapeutics in the 4th quarter worth approximately $98,000. Finally, Headlands Technologies LLC purchased a new position in shares of Celldex Therapeutics in the second quarter worth approximately $125,000.
Analyst Ratings Changes
Several research firms have weighed in on CLDX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Monday, April 20th. Barclays raised their target price on Celldex Therapeutics from $45.00 to $48.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Wells Fargo & Company boosted their price target on Celldex Therapeutics from $38.00 to $54.00 and gave the company an “overweight” rating in a report on Wednesday, May 13th. UBS Group upped their price target on Celldex Therapeutics from $38.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, June 10th. Finally, Wall Street Zen raised Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Celldex Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $49.30.
Celldex Therapeutics Price Performance
Shares of CLDX stock traded up $0.13 on Friday, hitting $39.11. 694,010 shares of the stock traded hands, compared to its average volume of 1,288,631. The firm has a market cap of $3.07 billion, a price-to-earnings ratio of -9.18 and a beta of 0.90. Celldex Therapeutics, Inc. has a 52 week low of $19.72 and a 52 week high of $40.30. The firm has a 50 day simple moving average of $32.98 and a two-hundred day simple moving average of $30.02.
Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.03). The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.80 million. Sell-side analysts forecast that Celldex Therapeutics, Inc. will post -4.36 EPS for the current year.
Celldex Therapeutics Profile
Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.
Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.
Featured Stories
- Five stocks we like better than Celldex Therapeutics
- Starbucks Builds Sovereign AI to Cut $400 Million in Software Costs
- Power Struggle: Wolfspeed Sues Navitas Over AI Chips
- Why WD-40 Is Proving Great Businesses Never Go Out of Style
- Pushing the Edge: Super Micro Computer Reboots the AI Landscape
Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report).
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-tbk-logo-1200x675.png){kind=logo}
